Indivior Pharmaceuticals annual stock-based compensation
2021
2022
2023
2024
2025
Indivior Pharmaceuticals Stock-Based Compensation Growth & History (INDV)
Indivior Pharmaceuticals's stock-based compensation was $26.0M for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $26.0M | $2.0M | +8.33% |
| 2024 | 2024-12-31 | $24.0M | $3.0M | +14.29% |
| 2023 | 2023-12-31 | $21.0M | $5.0M | +31.25% |
| 2022 | 2022-12-31 | $16.0M | $5.0M | +45.45% |
| 2021 | 2021-12-31 | $11.0M | — | — |
Indivior Pharmaceuticals quarterly stock-based compensation
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.0M | $3.0M | +37.50% |
| Q1 2026 | 2026-03-31 | $9.0M | $3.0M | +50.00% |
| Q4 2025 | 2025-12-31 | $5.0M | −$1.0M | −16.67% |
| Q3 2025 | 2025-09-30 | $7.0M | $1.0M | +16.67% |
| Q2 2025 | 2025-06-30 | $8.0M | $2.0M | +33.33% |
| Q1 2025 | 2025-03-31 | $6.0M | $0 | 0.00% |
| Q4 2024 | 2024-12-31 | $6.0M | — | — |
| Q3 2024 | 2024-09-30 | $6.0M | — | — |
| Q2 2024 | 2024-06-30 | $6.0M | — | — |
| Q1 2024 | 2024-03-31 | $6.0M | — | — |
Indivior Pharmaceuticals stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Indivior Pharmaceuticals's stock-based compensation increased from $11.0M to $26.0M, a change of $15.0M. The latest reported quarter, Q2 2026, shows $11.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals source filings ↗